TY - JOUR
T1 - Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer
AU - Rosenberger, I.
AU - Strauss, A.
AU - Dobiasch, S.
AU - Weis, C.
AU - Szanyi, S.
AU - Gil-Iceta, L.
AU - Alonso, E.
AU - González Esparza, M.
AU - Gómez-Vallejo, V.
AU - Szczupak, B.
AU - Plaza-García, S.
AU - Mirzaei, S.
AU - Israel, L. L.
AU - Bianchessi, S.
AU - Scanziani, E.
AU - Lellouche, J. P.
AU - Knoll, P.
AU - Werner, J.
AU - Felix, K.
AU - Grenacher, L.
AU - Reese, T.
AU - Kreuter, J.
AU - Jiménez-González, M.
N1 - Publisher Copyright: © 2015 Elsevier B.V.
PY - 2015/9/28
Y1 - 2015/9/28
N2 - Abstract Highly aggressive cancer types such as pancreatic cancer possess a mortality rate of up to 80% within the first 6 months after diagnosis. To reduce this high mortality rate, more sensitive diagnostic tools allowing an early stage medical imaging of even very small tumours are needed. For this purpose, magnetic, biodegradable nanoparticles prepared using recombinant human serum albumin (rHSA) and incorporated iron oxide (maghemite, γ-Fe2O3) nanoparticles were developed. Galectin-1 has been chosen as target receptor as this protein is upregulated in pancreatic cancer and its precursor lesions but not in healthy pancreatic tissue nor in pancreatitis. Tissue plasminogen activator derived peptides (t-PA-ligands), that have a high affinity to galectin-1 have been chosen as target moieties and were covalently attached onto the nanoparticle surface. Improved targeting and imaging properties were shown in mice using single photon emission computed tomography-computer tomography (SPECT-CT), a handheld gamma camera, and magnetic resonance imaging (MRI).
AB - Abstract Highly aggressive cancer types such as pancreatic cancer possess a mortality rate of up to 80% within the first 6 months after diagnosis. To reduce this high mortality rate, more sensitive diagnostic tools allowing an early stage medical imaging of even very small tumours are needed. For this purpose, magnetic, biodegradable nanoparticles prepared using recombinant human serum albumin (rHSA) and incorporated iron oxide (maghemite, γ-Fe2O3) nanoparticles were developed. Galectin-1 has been chosen as target receptor as this protein is upregulated in pancreatic cancer and its precursor lesions but not in healthy pancreatic tissue nor in pancreatitis. Tissue plasminogen activator derived peptides (t-PA-ligands), that have a high affinity to galectin-1 have been chosen as target moieties and were covalently attached onto the nanoparticle surface. Improved targeting and imaging properties were shown in mice using single photon emission computed tomography-computer tomography (SPECT-CT), a handheld gamma camera, and magnetic resonance imaging (MRI).
KW - Handheld gamma camera
KW - Maghemite
KW - Magnetic resonance imaging (MRI)
KW - Single photon emission computed tomography-computer tomography (SPECT-CT)
KW - rHSA nanoparticles
KW - t-PA-ligands to galectins
KW - t-PApeptide1<inf>LAC</inf>
UR - http://www.scopus.com/inward/record.url?scp=84938072102&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jconrel.2015.07.017
DO - https://doi.org/10.1016/j.jconrel.2015.07.017
M3 - مقالة
C2 - 26192099
SN - 0168-3659
VL - 214
SP - 76
EP - 84
JO - Journal of Controlled Release
JF - Journal of Controlled Release
M1 - 7764
ER -
